XML 16 R25.htm IDEA: XBRL DOCUMENT v2.4.0.6
Selected Quarterly Financial Information (UNAUDITED)
 12 Months Ended
Dec. 31, 2011
Selected Quarterly Financial Information (UNAUDITED) [Abstract]  
Selected Quarterly Financial Information (UNAUDITED)
19. Selected Quarterly Financial Information (UNAUDITED)
 
 
 
First Quarter
 
 
Second
Quarter
 
 
Third Quarter
 
 
Fourth
Quarter
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Year Ended December 31, 2011
 
 
 
 
 
 
 
 
 
 
 
 
Revenues
 
$
824,629
 
 
$
755,553
 
 
$
1,143,054
 
 
$
1,631,526
 
Operating expenses
 
 
4,850,516
 
 
 
5,736,547
 
 
 
5,375,419
 
 
 
7,078,711
 
Loss from operations
 
 
(4,027,887
)
 
 
(4,980,994
)
 
 
(4,232,365
)
 
 
(5,447,185
)
Net loss attributable to BioTime, Inc.
 
 
(3,362,132
)
 
 
(4,277,928
)
 
 
(3,737,626
)
 
 
(5,137,814
)
Basic and diluted net loss per share
 
 
(0.07
)
 
 
(0.06
)
 
 
(0.08
)
 
 
(0.10
)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Year Ended December 31, 2010
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenues
 
$
767,127
 
 
$
680,278
 
 
$
815,284
 
 
$
1,417,611
 
Operating expenses
 
 
2,093,249
 
 
 
2,995,702
 
 
 
3,272,988
 
 
 
5,170,494
 
Loss from operations
 
 
(1,326,122
)
 
 
(2,315,424
)
 
 
(2,457,704
)
 
 
(3,752,883
)
Net loss attributable to BioTime, Inc.
 
 
(1,286,764
)
 
 
(2,259,775
)
 
 
(4,671,162
)
 
 
(2,966,917
)
Basic and diluted net loss per share
 
 
(0.04
)
 
 
(0.06
)
 
 
(0.11
)
 
 
(0.06
)

BioTime did not amortize deferred license fees until the fourth quarter of 2010.  Because BioTime modified its procedure for amortizing deferred license fees in the fourth quarter, certain differences resulted in BioTime's operating expenses, total expenses, and loss for the fourth quarter of 2010 as compared to the previous quarters of 2010.  BioTime treated those differences as a correction of an error totaling $23,792 for first quarter, $27,375 each for the second and third quarter.  BioTime does not believe that those differences were material to its results of operations for those prior quarters.  Because BioTime did not record the effect of that error in its financial statements for the quarters ended March 31, 2010, June 30, 2010 and September 31, 2010 due to the immaterial impact on those financial statements, it has recorded in research and development expenses in the fourth quarter for 2010 an additional $78,542, representing the amortization not previously recorded in the first three quarters in 2010.  See Note 7 for an explanation of the effect on BioTime's financial statements for the years ended December 31, 2010, 2009, and 2008.